Prevention is Better Than Cure
“An ounce of prevention is worth a pound of cure.”
Benjamin Franklin
About Biotav Shield
We are building a controllable oral live vaccine platform targeting respiratory pathogens, designed to block infection at its point of entry through scalable, needle-free delivery.
Our Vision:
To redefine global pandemic preparedness with accessible, high-efficacy vaccines.
Our Mission:
To develop next-generation vaccines that deliver both mucosal and systemic immunity, addressing key limitations of current approaches.
Market Opportunity
Despite widespread vaccination, major gaps remain:
Limited prevention of infection and transmission;
Rapid waning immunity requiring frequent boosters;
Injection-based delivery constraining scalability;
Cold-chain logistics limiting global reach.
These shortcomings leave a multi-billion-dollar global market underserved and the world vulnerable to future respiratory pandemics.
Technology Summary
Our platform enables oral delivery of live, controllable vaccines that induce immunity at mucosal surfaces while also generating systemic protection. This approach has the potential to improve efficacy, simplify distribution, and significantly expand global access.
Our Vision:
To redefine global pandemic preparedness with accessible, high-efficacy vaccines.
Our Mission:
To develop next-generation vaccines that deliver both mucosal and systemic immunity, addressing key limitations of current approaches.
Market Opportunity
Despite widespread vaccination, major gaps remain:
Limited prevention of infection and transmission;
Rapid waning immunity requiring frequent boosters;
Injection-based delivery constraining scalability;
Cold-chain logistics limiting global reach.
These shortcomings leave a multi-billion-dollar global market underserved and the world vulnerable to future respiratory pandemics.
Technology Summary
Our platform enables oral delivery of live, controllable vaccines that induce immunity at mucosal surfaces while also generating systemic protection. This approach has the potential to improve efficacy, simplify distribution, and significantly expand global access.
Biotav Shield offers:
A platform extensible beyond COVID-19
Potential Multi Valent Vaccine
Opportunity for early partnership or acquisition
Our Approach
Biotav Shield is developing a platform for orally delivered live attenuated vaccines, designed to activate immunity where infection begins.
- Oral delivery via enteric capsule
- Induction of mucosal (IgA) and systemic immunity
- Designed for durable protection and transmission reduction
Our Technology
Biotav Shield offers:
A platform extensible beyond COVID-19, I.e. Potential integration with existing vaccine portfolios Opportunity for early partnership or acquisition the breaking through technology for respiratory pathogens Blocking infection at the point of entry — with scalable, needle-free immunity.
Developing next-generation vaccines delivery platform, designed for mucosal and systemic protection. Current vaccines fall short where it matters most: Limited protection against infection and transmission Waning immunity requiring repeated boosters Injection-based delivery limiting scalability Cold-chain dependence restricting global access Result: The world remains underprepared for respiratory pandemics.
Our Approach Biotav Shield is developing a platform for orally delivered live attenuated vaccines, designed to activate immunity where infection begins. Oral delivery via enteric capsule Induction of mucosal (IgA) and systemic immunity Designed for durable protection and transmission reduction Dr. Yair Saar, DVM Founder & Chief Executive Officer Dr. Yair Saar is the Founder and Chief Executive Officer of Biotav Shield Ltd, where he leads the company’s mission to deliver scientific breakthroughs that can transform patient health.
His leadership focuses on advancing innovative technologies, accelerating drug development, and building a science-driven organization dedicated to improving global healthcare. With more than 30 years of experience in vaccinology and biotechnology, Dr. Saar has led international collaborations and business development across multiple markets, including China and Austria.
His global perspective has strengthened his understanding of healthcare systems, patient needs, and the importance of innovation in modern medicine.
A platform extensible beyond COVID-19, I.e. Potential integration with existing vaccine portfolios Opportunity for early partnership or acquisition the breaking through technology for respiratory pathogens Blocking infection at the point of entry — with scalable, needle-free immunity.
Developing next-generation vaccines delivery platform, designed for mucosal and systemic protection. Current vaccines fall short where it matters most: Limited protection against infection and transmission Waning immunity requiring repeated boosters Injection-based delivery limiting scalability Cold-chain dependence restricting global access Result: The world remains underprepared for respiratory pandemics.
Our Approach Biotav Shield is developing a platform for orally delivered live attenuated vaccines, designed to activate immunity where infection begins. Oral delivery via enteric capsule Induction of mucosal (IgA) and systemic immunity Designed for durable protection and transmission reduction Dr. Yair Saar, DVM Founder & Chief Executive Officer Dr. Yair Saar is the Founder and Chief Executive Officer of Biotav Shield Ltd, where he leads the company’s mission to deliver scientific breakthroughs that can transform patient health.
His leadership focuses on advancing innovative technologies, accelerating drug development, and building a science-driven organization dedicated to improving global healthcare. With more than 30 years of experience in vaccinology and biotechnology, Dr. Saar has led international collaborations and business development across multiple markets, including China and Austria.
His global perspective has strengthened his understanding of healthcare systems, patient needs, and the importance of innovation in modern medicine.
Cutting Edge Technology
Multi Valent Immunity
Engineered to activate both mucosal (IgA) and systemic immunity, helping block infection at the point of entry while providing long-lasting protection.
Pandemic Readiness Solutions
Addressing critical gaps in current vaccines by improving infection control, reducing transmission, and eliminating cold-chain and booster dependency challenges.
Strategic Partnerships & Platform Integration
A flexible platform designed to expand beyond COVID-19, integrate with existing vaccine portfolios, and support partnerships, licensing, and co-development opportunities.
Investment Highlights
Contact
- Office@biotavshield.com
- Mon-Fri - 08:00-19:00
TAKE ACTION NOW
DON'T WAIT ANY LONGER